Latest Royalty Revenue News

Anagenics says restructuring has reduced quarterly operating cash outflows to A$10,000 and put the business into profitable trading. The company ended September with A$532,000 in cash, while A$377,000 of newly invoiced royalty revenue was still to be received.

Riedel Resources has completed the equity-funded acquisition of the Cosmo and Mt Venn gold projects, expanding its exploration portfolio beyond Arizona. But the annual report carries a material going-concern uncertainty, leaving future drilling dependent on further capital and execution.

High Peak Royalties reported a A$1.59 million FY26 profit after completing its Northstar transaction, which generated a A$1.90 million accounting gain. The underlying royalty business was softer, with royalty revenue and operating cash flow both declining year on year.

Deterra Royalties has paid US$74.15 million for a royalty covering most of Ivanhoe Electric’s Santa Cruz copper project in Arizona. The deal adds a third core asset, but its projected returns still depend on financing, permitting and a targeted 2029 production start.

Cullen Resources posted a $340,251 FY2026 profit after selling its Wyloo iron ore royalty for $1.5 million. The result came with a qualified audit opinion over its remaining iron ore-related assets and a warning that further capital raisings will be needed.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.

Deterra Royalties delivered a 5% increase in statutory net profit to $164.2 million for FY26, underpinned by record Mining Area C volumes and strategic asset sales. The company declared a fully franked final dividend of 10.8 cents, maintaining a 75% payout ratio, while advancing the Thacker Pass lithium project on schedule for late 2027 production.

Deterra Royalties reported a record A$61.8 million iron ore royalty revenue from Mining Area C in the June 2026 quarter, alongside significant progress at the Thacker Pass lithium project with US$1.21 billion drawn from a US Department of Energy loan.

Starpharma Holdings is raising approximately $32 million through a fully underwritten 1-for-7.5 renounceable entitlement offer priced at $0.57 per share, discounting the stock by 25%. Proceeds will fund the DEP HER2-Lu Phase 1 trial and expand its dendrimer-based oncology pipeline.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Calix’s Leilac unit has teamed up with Ambuja Cements to trial a commercial-scale carbon capture retrofit at the Sanghi plant, aiming to slash emissions and fuel costs without upfront capital.